Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use
| dc.rights.license | open | en_US |
| dc.contributor.author | BERTIN, Celian | |
| dc.contributor.author | BEZIN, Julien | |
| dc.contributor.author | CHENAF, Chouki | |
| dc.contributor.author | DELORME, Jessica | |
| dc.contributor.author | KERCKHOVE, Nicolas | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PARIENTE, Antoine
IDREF: 13395711X | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DAUBECH-TOURNIER, Marie | |
| dc.contributor.author | AUTHIER, Nicolas | |
| dc.date.accessioned | 2022-10-14T13:09:30Z | |
| dc.date.available | 2022-10-14T13:09:30Z | |
| dc.date.issued | 2022-06-30 | |
| dc.identifier.issn | 1664-0640 (Print) 1664-0640 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170025 | |
| dc.description.abstractEn | BACKGROUND: National health monitoring agencies have reported the alternative use of morphine sulfate painkiller for maintenance treatment of opioid use disorder (OUD), associated with a potential increase in overdose risk. OBJECTIVES: This study sought to assess the prevalence of regular and occasional legally prescribed morphine use in patients treated for OUD and compare their characteristics to those of patients receiving conventional opioid maintenance treatment (OMT), buprenorphine or methadone. Then, we assessed the factors associated with opioid overdose risk. METHODS: Data were extracted from the French national healthcare system database, covering the entire population in 2015. Diagnosis associated with hospital discharge and long-term disease codes were extracted to select the population and identify outcomes and covariates. OUD non-chronic pain patients were divided into regular (≤35 days between dispensing and ≥3 months of continuous treatment duration) morphine users, and occasional users. Their sociodemographic and health characteristics were compared to OMT controls. A multivariate logistic regression model was performed to determine factors associated with opioid overdose. RESULTS: In patients treated for OUD, 2,237 (2.2%) morphine users (1,288 regular and 949 occasional), 64,578 (63.7%) buprenorphine and 34,638 (34.1%) methadone controls were included. The prevalence of regular morphine use among patients treated for OUD regularly receiving an opioid was 1.3%. Compared to users who receive morphine regularly, occasional users had an increased risk of overdose [OR = 2.2 (1.5-3.3)], while the risk was reduced in the buprenorphine group [OR = 0.5 (0.4-0.7)] and not significantly different for methadone [OR = 1.0 (0.7-1.4)]. Other overdose risk factors were low-income, comorbidity, i.e., psychiatric conditions, alcohol use disorder or complications related to intravenous drug use, and coprescription with benzodiazepines or pregabalin. These factors were more frequent in morphine groups. CONCLUSIONS: Patients that were prescribed oral morphine represented a small minority of the treated for OUD. The poorer health condition affected by numerous comorbidities and higher risk of opioid overdose in patients treated with oral morphine compared with OMT controls points toward the need to better supervise the practices of these patients, to strengthen multidisciplinary care and risk reduction measures. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Opioid | |
| dc.subject.en | Morphine | |
| dc.subject.en | Substance use disorder | |
| dc.subject.en | Overdose | |
| dc.subject.en | Opioid maintenance treatment | |
| dc.subject.en | Healthcare database | |
| dc.subject.en | Morphine dependence | |
| dc.subject.en | Prescription medication misuse | |
| dc.title.en | Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3389/fpsyt.2022.893590 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35845444 | en_US |
| bordeaux.journal | Frontiers in Psychiatry | en_US |
| bordeaux.volume | 13 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03815296 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-10-14T13:09:33Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Psychiatry&rft.date=2022-06-30&rft.volume=13&rft.eissn=1664-0640%20(Print)%201664-0640%20(Linking)&rft.issn=1664-0640%20(Print)%201664-0640%20(Linking)&rft.au=BERTIN,%20Celian&BEZIN,%20Julien&CHENAF,%20Chouki&DELORME,%20Jessica&KERCKHOVE,%20Nicolas&rft.genre=article |
